Merck & Co. is eyeing Austin, Texas, for a 600-person IT shop, one of four around the globe, as it amps up in personalized and preventative medicine.

Sanofi and Regeneron's cholesterol-fighter Praluent might have had a chance to take the lead in the PCSK9 sales race, but that fuel injection didn’t come…

A few years ago, emerging markets were souped-up engines heating up pharma growth. Now, with economic slowdowns in key markets such as China, they’ve moved…

Roche’s much-anticipated multiple sclerosis drug Ocrevus (ocrelizumab) has topped up with more competitive data that could help it gain a quick hold in the…

Diabetes powerhouse Sanofi and Verily, its tech partner, are plowing close to $500 million into a joint venture that will take their digital disease-management…

Not enough drugmakers on the “smart inhaler” bandwagon for you? Well, go ahead and add AstraZeneca to the list.

Payers who’ve balked at next-gen cholesterol meds now have more justification. A new JAMA study concluded that Amgen, Sanofi and Regeneron would have to slash…

Medivation posted second-quarter numbers on Tuesday, and they offer more evidence why Big Pharma and Big Biotech are stumbling over themselves to snap up the…

More and more companies are going “beyond the pill” when it comes to rolling out new products and services that help boost uptake of or compliance with their…

JAMA lit a fuse in pharma last week with a study associating free meals for doctors with increases in branded prescriptions. Here's one marketing expert…

Data and Analytics